CalciMedica, Inc. (CALC) Stock Analysis & Investment Frameworks
CalciMedica, Inc. (CALC) stock analysis on Invetso. Review CalciMedica, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
CalciMedica, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
CalciMedica, Inc. Key Financial Metrics
- Market Cap: $4.28M
- Revenue: $N/A
- ROE: 3398.40%
- ROIC: -122.56%
- Dividend Yield: N/A
About CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
CalciMedica, Inc. Investment Frameworks
Invetso analyzes CalciMedica, Inc. (CALC) across the following frameworks:
- CalciMedica, Inc. 10Y Growth Potential
- CalciMedica, Inc. Scenario Analysis
- CalciMedica, Inc. Risks & Opportunities
- CalciMedica, Inc. Economic Moat
- CalciMedica, Inc. Business Model
- CalciMedica, Inc. Management
- CalciMedica, Inc. SWOT Analysis
- CalciMedica, Inc. Porter's 5 Forces
- CalciMedica, Inc. PESTLE Analysis
- CalciMedica, Inc. ESG Analysis